Angiotensin-II receptor blockers: benefits beyond blood pressure reduction? (Q36060436)

11 August 2017

1 reference

title

Angiotensin-II receptor blockers: benefits beyond blood pressure reduction? (English)

1 reference

11 August 2017

1

Volpe M

1 reference

11 August 2017

Ruilope LM

2

1 reference

11 August 2017

McInnes GT

series ordinal

3

1 reference

11 August 2017

Waeber B

series ordinal

4

1 reference

11 August 2017

Weber MA

series ordinal

5

1 reference

11 August 2017

1 May 2005

1 reference

Journal of Human Hypertension

11 August 2017

1 reference

11 August 2017

19

1 reference

11 August 2017

5

1 reference

11 August 2017

331-339

1 reference

https://scigraph.springernature.com/pub.10.1038/sj.jhh.1001831

11 August 2017

0 references

cites work

Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1001831

Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. HOT Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1001831

Survival in treated hypertension: follow up study after two decades

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1001831

Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1001831

Randomised trial of a perindopril-based blood-pressure-lowering regimen among 6105 individuals with previous stroke or transient ischaemic attack

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1001831

Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1001831

Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1001831

Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1001831

ACE inhibition and cardiovascular mortality and morbidity in essential hypertension: the end of the search or a need for further investigations?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1001831

The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure<SUBTITLE>The JNC 7 Report</SUBTITLE>

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1001831

Trends in the Prevalence, Awareness, Treatment, and Control of Hypertension in the Adult US Population : Data From the Health Examination Surveys, 1960 to 1991

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1001831

More evidence on blocking the renin–angiotensin–aldosterone system in cardiovascular disease and the long-term treatment of hypertension: data from recent clinical trials (CHARM, EUROPA, ValHEFT, HOPE-TOO and SYST-EUR2)

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1001831

Continuation of initial antihypertensive medication after 1 year of therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1001831

Losartan, an angiotensin II (AT1) receptor antagonist, preserves cerebral blood flow in hypertensive patients with a history of stroke

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1001831

Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1001831

Valsartan and hydrochlorothiazide in patients with essential hypertension. A multiple dose, double-blind, placebo controlled trial comparing combination therapy with monotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1001831

The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1001831

Angiotensin II receptor antagonists

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1001831

Angiotensin II AT2 receptor subtype: an uprising frontier in cardiovascular disease?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1001831

Effects of losartan on cardiovascular morbidity and mortality in patients with isolated systolic hypertension and left ventricular hypertrophy: a Losartan Intervention for Endpoint Reduction (LIFE) substudy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1001831

Effect of losartan on sudden cardiac death in people with diabetes: data from the LIFE study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1001831

Blood pressure dependent and independent effects of antihypertensive treatment on clinical events in the VALUE Trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1001831

VALUE trial: Long-term blood pressure trends in 13,449 patients with hypertension and high cardiovascular risk

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1001831

Effect of angiotensin-converting-enzyme inhibition compared with conventional therapy on cardiovascular morbidity and mortality in hypertension: the Captopril Prevention Project (CAPPP) randomised trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1001831

Plasma renin activity levels in hypertensive persons: their wide range and lack of suppression in diabetic and in most elderly patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1001831

Adverse prognostic significance of new diabetes in treated hypertensive subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1001831

Angiotensin blockade prevents type 2 diabetes by formation of fat cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1001831

Microalbuminuria reduction with valsartan in patients with type 2 diabetes mellitus: a blood pressure-independent effect

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1001831

Does albuminuria predict cardiovascular outcome on treatment with losartan versus atenolol in hypertension with left ventricular hypertrophy? A LIFE substudy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1001831

A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1001831

Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function intolerant to angiotensin-converting-enzyme inhibitors: the CHARM-Alternative trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1001831

Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensin-converting-enzyme inhibitors: the CHARM-Added trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1001831

Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: the CHARM-Preserved Trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1001831

Effects of candesartan on mortality and morbidity in patients with chronic heart failure: the CHARM-Overall programme

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1001831

Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1001831

Mortality in patients of the Glasgow Blood Pressure Clinic

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1001831

7 January 2021

Effects of ACE inhibitors, calcium antagonists, and other blood-pressure-lowering drugs: results of prospectively designed overviews of randomised trials. Blood Pressure Lowering Treatment Trialists' Collaboration

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1001831

7 January 2021

Association of the renin-sodium profile with the risk of myocardial infarction in patients with hypertension

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1001831

7 January 2021

2003 European Society of Hypertension-European Society of Cardiology guidelines for the management of arterial hypertension

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1001831

7 January 2021

Improved hypertension management and control: results from the health survey for England 1998

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1001831

7 January 2021

Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT)

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1001831

7 January 2021

Insulin resistance and hypertension

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1001831

7 January 2021

Identifiers

DOI

10.1038/SJ.JHH.1001831

1 reference

11 August 2017

1 reference